CytoSorbents president and COO Vincent Capponi.

While many Route 1 corridor pharmaceutical companies have altered their focus to research vaccines and treatments for COVID-19, one was able to immediately put its technology into use.

As early as January CytoSorbents, based on Deer Park Drive in Monmouth Junction, published a paper showing the potential for its CytoSorb blood-filtering device to help treat the cytokine storm immune response that can occur in severe coronavirus cases.

In February CytoSorbents announced that it had partnered with a China-based company to gain fast-tracked regulatory approval for use of the device in hospitals in Wuhan, the virus’ original epicenter. The device is already used in 58 countries to treat sepsis.

Emergency approval for use of CytoSorb to fight coronavirus in the U.S. was granted by the Food and Drug Administration in April. Now CytoSorbents has announced several partnerships to commercialize the product across the country.

On August 17 the company announced an agreement with Tennessee-based Surgical Partners to market the product in Florida and with Massachusetts-based medical device distribution company InvoSurg Inc. to commercialize CytoSorb in the northeast and mid-Atlantic states, from Maine to Virginia.

“Physicians have told us that they need better treatment options to help them regain control of their critically-ill COVID-19 patients,” CytoSorbents president and COO Vincent Capponi said in a statement. “Partnerships like these with InvoSurg and Surgical Partners, are intended to bring CytoSorb rapidly to physicians and COVID-19 patients in the broader U.S. market in a timely and cost-effective manner.

“CytoSorb has been used in more than 1,200 COVID-19 patients worldwide. CytoSorb is plug-and-play compatible with a wide range of blood pumps that exist in hospitals today including hemoperfusion, dialysis, continuous renal replacement therapy (CRRT), and extracorporeal membrane oxygenation (ECMO) machines. We are very proud to begin working with Surgical Partners and InvoSurg to bring CytoSorb directly to these areas of the United States that have been hard hit by COVID-19.”

CytoSorb’s U.S. reach was expanded again August 24 when a partnership with Terumo Cardiovascular was announced to distribute the purification device to hospitals in 10 coronavirus hot spots. The Michigan-based subsidiary of the Japanese provider of cardiovascular surgery technologies will be the exclusive seller of CytoSorb to hospitals in Alabama, Arizona, California, Georgia, Louisiana, Mississippi, New Mexico, Oregon, Texas, and Washington.

CytoSorbents Inc. (CTSO), 7 Deer Park Drive, Suite K, Monmouth Junction 08852. 732-329-8885. Phillip Chan, CEO. www.cytosorbents.com.

Facebook Comments